RS63104B1 - Sastavi za ubrizgavanje koji sadrže letrozol ili anastrozol - Google Patents
Sastavi za ubrizgavanje koji sadrže letrozol ili anastrozolInfo
- Publication number
- RS63104B1 RS63104B1 RS20220307A RSP20220307A RS63104B1 RS 63104 B1 RS63104 B1 RS 63104B1 RS 20220307 A RS20220307 A RS 20220307A RS P20220307 A RSP20220307 A RS P20220307A RS 63104 B1 RS63104 B1 RS 63104B1
- Authority
- RS
- Serbia
- Prior art keywords
- dmso
- composition
- situ
- pla
- aromatase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201231271A ES2390439B1 (es) | 2012-08-03 | 2012-08-03 | Composición inyectable |
| PCT/EP2013/065877 WO2014019972A1 (en) | 2012-08-03 | 2013-07-29 | Injectable compositions comprising letrozole or anastrozole |
| EP13742226.7A EP2879661B1 (en) | 2012-08-03 | 2013-07-29 | Injectable compositions comprising letrozole or anastrozole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS63104B1 true RS63104B1 (sr) | 2022-04-29 |
Family
ID=47046938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220307A RS63104B1 (sr) | 2012-08-03 | 2013-07-29 | Sastavi za ubrizgavanje koji sadrže letrozol ili anastrozol |
Country Status (31)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10285936B2 (en) * | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| LT2394663T (lt) | 2010-05-31 | 2022-02-10 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams |
| PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| CA3157003A1 (en) * | 2019-10-07 | 2021-04-15 | Oak Crest Institute Of Science | Orally implantable drug delivery device |
| KR102319352B1 (ko) | 2021-02-03 | 2021-10-29 | 바이오메디팜 어업회사법인 주식회사 | 첨연어의 수컷화 비율을 높이는 비호르몬적 방법 |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| WO2025153747A1 (es) * | 2024-01-17 | 2025-07-24 | Laboratorios Farmacéuticos Rovi, S.A. | Composiciones y esquemas de dosificación de inhibidores de aromatasa mejorados |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| GB0517673D0 (en) * | 2005-08-31 | 2005-10-05 | Astrazeneca Ab | Formulation |
| GB0517674D0 (en) * | 2005-08-31 | 2005-10-05 | Astrazeneca Ab | Formulation |
| AR063120A1 (es) * | 2006-10-05 | 2008-12-30 | Panacea Biotec Ltd | Composiciones inyectables de deposito y proceso para prepararlas |
| WO2009060473A2 (en) * | 2007-11-06 | 2009-05-14 | Panacea Biotec Limited | Injectable compositions, processes and uses thereof |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| US20100144687A1 (en) | 2008-12-05 | 2010-06-10 | Glaser Rebecca L | Pharmaceutical compositions containing testosterone and an aromatase inhibitor |
| LT2394663T (lt) * | 2010-05-31 | 2022-02-10 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams |
| TWI538687B (zh) | 2010-11-24 | 2016-06-21 | 杜瑞克公司 | 生物可降解之藥物遞送組成物 |
-
2012
- 2012-08-03 ES ES201231271A patent/ES2390439B1/es active Active
-
2013
- 2013-07-29 SI SI201331978T patent/SI2879661T1/sl unknown
- 2013-07-29 BR BR112015002370-3A patent/BR112015002370B1/pt active IP Right Grant
- 2013-07-29 AU AU2013298705A patent/AU2013298705B2/en active Active
- 2013-07-29 DK DK13742226.7T patent/DK2879661T3/da active
- 2013-07-29 SG SG11201500793VA patent/SG11201500793VA/en unknown
- 2013-07-29 WO PCT/EP2013/065877 patent/WO2014019972A1/en not_active Ceased
- 2013-07-29 PL PL13742226T patent/PL2879661T3/pl unknown
- 2013-07-29 MY MYPI2015700311A patent/MY194726A/en unknown
- 2013-07-29 LT LTEPPCT/EP2013/065877T patent/LT2879661T/lt unknown
- 2013-07-29 PT PT137422267T patent/PT2879661T/pt unknown
- 2013-07-29 HU HUE13742226A patent/HUE058322T2/hu unknown
- 2013-07-29 HR HRP20220537TT patent/HRP20220537T1/hr unknown
- 2013-07-29 CA CA2880347A patent/CA2880347C/en active Active
- 2013-07-29 RS RS20220307A patent/RS63104B1/sr unknown
- 2013-07-29 CN CN201380041244.8A patent/CN104519870B/zh active Active
- 2013-07-29 NZ NZ705558A patent/NZ705558A/en unknown
- 2013-07-29 IN IN1711DEN2015 patent/IN2015DN01711A/en unknown
- 2013-07-29 EP EP13742226.7A patent/EP2879661B1/en active Active
- 2013-07-29 ES ES13742226T patent/ES2926715T3/es active Active
- 2013-07-29 MX MX2015001513A patent/MX362874B/es active IP Right Grant
- 2013-07-29 UA UAA201501775A patent/UA113317C2/uk unknown
- 2013-07-29 EA EA201500196A patent/EA033316B1/ru unknown
- 2013-07-29 JP JP2015524749A patent/JP6317348B2/ja active Active
- 2013-07-29 KR KR1020157005601A patent/KR101892109B1/ko active Active
- 2013-07-29 SM SM20220127T patent/SMT202200127T1/it unknown
-
2015
- 2015-01-29 IL IL236981A patent/IL236981B/en unknown
- 2015-02-02 PH PH12015500231A patent/PH12015500231A1/en unknown
- 2015-02-03 CL CL2015000259A patent/CL2015000259A1/es unknown
- 2015-02-26 MA MA37870A patent/MA37870B1/fr unknown
- 2015-03-02 ZA ZA2015/01426A patent/ZA201501426B/en unknown
-
2022
- 2022-04-07 CY CY20221100263T patent/CY1125157T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS63104B1 (sr) | Sastavi za ubrizgavanje koji sadrže letrozol ili anastrozol | |
| US10912735B2 (en) | Injectable composition with aromatase inhibitor | |
| KR101892496B1 (ko) | 팔리페리돈 임플란트 제형 | |
| RS55190B1 (sr) | Antipsihotička injektabilna deponujuća kompozicija | |
| RS53205B (sr) | Formulacija implantabilnog paliperidona | |
| Wang et al. | Parenteral thermo-sensitive organogel for schizophrenia therapy, in vitro and in vivo evaluation | |
| BRPI0909630B1 (pt) | Composição em suspensão aquosa particularmente adequada para injeção dentro do olho | |
| JP7752051B2 (ja) | 長時間作用型注射用製剤およびその使用 | |
| TR201809874T4 (tr) | Somatostati̇n analoglarinin sürekli̇ salimi i̇çi̇n farmasöti̇k bi̇leşi̇mleri̇n hazirlanmasi süreci̇. | |
| Cespi et al. | Evaluation of thermosensitive poloxamer 407 gel systems for the sustained release of estradiol in a fish model | |
| WO2016036588A1 (en) | Pharmaceutical suspensions containing etoricoxib | |
| RS62681B1 (sr) | Injektabilni sastav | |
| CN108143715A (zh) | 一种氟比洛芬酯注射液 | |
| HK1204551B (en) | Injectable compositions | |
| Negi et al. | Design and Analysis of an Emulgel Including Microcapsules of Etoricoxib | |
| WO2024168024A1 (en) | Degarelix organic solvent formulations | |
| JP2025186498A (ja) | 長時間作用型注射用製剤およびその使用 | |
| JP2025503286A (ja) | 疼痛治療用医薬組成物 | |
| JP2024516264A (ja) | 新規製剤 | |
| WO2021058651A1 (en) | Hydrogel compositions for the controlled and constant release of active agents | |
| Chantadee et al. | Vancomycin hydrochloride-loaded stearic acid/lauric acid in situ |